Bethesda, MD, United States of America

Polly Matzinger


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2004-2011

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Polly Matzinger: Pioneering Innovations in Hemophilia Treatment

Introduction

Polly Matzinger is a renowned inventor based in Bethesda, MD (US). She has made significant contributions to the field of immunology, particularly in the treatment of hemophilia. With a total of 3 patents, her work has paved the way for innovative approaches to managing antigen-deficiency diseases.

Latest Patents

Matzinger's latest patents include groundbreaking methods for the treatment of hemophilia. One notable patent is focused on the induction of tolerance by oral administration of factor VIII. This method involves orally administering a therapeutically effective amount of the deficient antigen, which is not present in a liposome. The approach aims to increase hemostasis in subjects with hemophilia A or B, thereby supplying exogenous clotting factors to the patients. Another patent details a similar oral treatment method for hemophilia, emphasizing the importance of inducing oral tolerance to improve patient outcomes.

Career Highlights

Throughout her career, Polly Matzinger has worked with prestigious organizations, including the National Institutes of Health, a component of the US Department of Health & Human Services, and Virginia Tech Intellectual Properties, Inc. Her work has been instrumental in advancing the understanding and treatment of hemophilia.

Collaborations

Matzinger has collaborated with notable colleagues, including Oral Alpan and Tirumalai Kamala. These partnerships have further enriched her research and contributed to her innovative approaches in the field.

Conclusion

Polly Matzinger's contributions to the treatment of hemophilia through her innovative patents highlight her role as a leading inventor in the medical field. Her work continues to inspire advancements in the management of antigen-deficiency diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…